Loading...
•
Jun 30, 2022
Corcept Therapeutics Q2 2022 Earnings Report
Announced second quarter financial results and provided corporate update.
Key Takeaways
Corcept Therapeutics reported Q2 2022 revenue of $103.4 million, a net income of $27.4 million, and a diluted net income per common share of $0.24. The company reiterated its 2022 revenue guidance of $400 - $430 million. Cash and investments increased to $382.0 million.
Revenue of $103.4 million, compared to $91.6 million in second quarter 2021
Reiterated 2022 revenue guidance of $400 – $430 million
Diluted net income per common share of $0.24, compared to $0.21 in second quarter 2021
Cash and investments of $382.0 million, compared to $368.1 million at March 31, 2022
Revenue by Segment
Forward Guidance
Corcept Therapeutics reiterated its 2022 revenue guidance of $400 – $430 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...